2023 World Conference on Lung Cancer (Posters)-P2.03. Effectiveness and Safety of Combining Bevacizumab and Fractionated Stereotactic Radiotherapy for Brain Metastases in NSCLC Patients

P2.03. Effectiveness and Safety of Combining Bevacizumab and Fractionated Stereotactic Radiotherapy for Brain Metastases in NSCLC Patients - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the effectiveness and safety of combining bevacizumab and fractionated stereotactic radiotherapy (FSRT) for brain metastases in non-small cell lung cancer (NSCLC) patients with stable extracranial disease status. NSCLC patients with brain metastases were recruited and assigned to receive FSRT along with bevacizumab. The primary endpoint of the study was intra-cranial progression-free survival (IPFS), and the secondary endpoints included overall survival (OS), progression-free survival (PFS), quality of life (QOL) score, and toxicities. The control group consisted of patients treated with whole-brain radiotherapy (WBRT) plus FSRT or FSRT only. <br /><br />Results showed that the combination of FSRT and bevacizumab achieved promising intracranial disease control. The estimated 1-year IPFS and OS rates were 77.4% and 74.8% respectively. The median PFS was 8.4 months. The FSRT plus bevacizumab group had a significantly higher 1-year IPFS rate compared to the control groups. The treatment-related toxicities of FSRT plus bevacizumab were mild with low incidence, including reversible mild hypertension and cerebral radio-necrosis. No signs of extra-lesional hemorrhage or progression of peri-lesional edema were found. Additionally, significant improvement in QOL was observed in symptomatic patients.<br /><br />In conclusion, the combination of FSRT with bevacizumab was tolerable and achieved promising intracranial disease control in NSCLC patients. QOL was maintained with a low incidence of cerebral radio-necrosis. This study suggests that this combination therapy could be an effective option for NSCLC patients with brain metastases.

Asset Subtitle

Rui Zhou

Meta Tag

Speaker Rui Zhou

Topic Metastatic NSCLC: Local Therapies

Keywords

bevacizumab

fractionated stereotactic radiotherapy

brain metastases

non-small cell lung cancer

extracranial disease

intra-cranial progression-free survival

overall survival

progression-free survival

quality of life

toxicities